X

Trial Profile

A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Encorafenib (Primary)
Indications Colorectal cancer; Malignant melanoma
Focus Adverse reactions; First in man
Sponsors Array BioPharma; Pfizer

Most Recent Events

31 Mar 2023 Status changed from active, no longer recruiting to completed.
15 Oct 2022 Planned End Date changed from 31 Jul 2022 to 7 Nov 2022.
11 May 2021 Planned End Date changed from 31 Jul 2021 to 31 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com